19:04 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
23:25 , Oct 24, 2018 |  BC Extra  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
22:45 , Sep 6, 2018 |  BC Extra  |  Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:35 , Aug 8, 2017 |  BC Extra  |  Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
21:49 , Jul 27, 2017 |  BC Innovations  |  Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
14:15 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Arthritis; pain Cell culture and mouse studies suggest a pyrazolopyridine-based GPR4 inhibitor could help treat arthritis or pain. Chemical synthesis of pyrazolopyridine analogs and testing in a human cell line yielded an oxadiazole-containing compound...
07:00 , May 9, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Diclofenac: Clinical trial data

Top-line data from a double-blind, German trial in 126 patients with grade I or II ankle sprains showed that twice-daily topical Pennsaid 2% for 8 days missed the primary endpoint of reducing pain on movement...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

Nuvo Pharmaceuticals (formerly Nuvo Research Inc. ) spun out its drug development business into stand-alone company Crescita. Nuvo Pharmaceuticals will focus on its Pennsaid diclofenac franchise. Crescita is developing topical formulations of drugs for dermatology...